Skip to main content
Humalog Home
Menu closed
Humalog Home
Globe Loading... Reveal available languages
  • House For Healthcare Providers
      • Efficacy
      • Device Options
      • Self Titration Dosing
    • Humalog U-200
    • Humalog Mixes
    • Savings & Support
  • For Consumers
Ask Lilly

We're here to help.

Phone Call:
1-800-LillyRx
(1-800-545-5979)
Link Visit Lilly Medical (HCP)
Question Submit a Question
Expand contact lilly

COVID-19 Update

Questions about Coronavirus? Click here for information about Lilly's Global COVID-19 Response



Now you have more choices when it comes to improving your patient's blood sugar control.

Humalog (insulin lispro injection) 100 units/mL logo
Humalog vial and KwikPen

CONTINUE TO HUMALOG.COM

Humalog is indicated to improve glycemic control in adults and children with diabetes mellitus.

Humalog is contraindicated during episodes of hypoglycemia and in patients who are hypersensitive to insulin lispro or any of its excipients.

Lyumjev (insulin lispro-aabc injection) 100 units/mL
Lyumjev vial and KwikPen

VISIT LYUMJEV.COM

Lyumjev is indicated to improve glycemic control in adults with diabetes mellitus.

Lyumjev is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin lispro-aabc or one of the excipients in Lyumjev.

Indication for Humalog Brand of Insulins and Lilly's Non-Branded Insulin Lispro Products

Humalog and Insulin Lispro Injection are rapid-acting insulin analogs indicated to improve glycemic control in adults and children with diabetes mellitus. Humalog Mix75/25 and Humalog Mix50/50, and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 are mixtures of intermediate-acting and rapid-acting insulin analogs indicated to improve glycemic control in patients with diabetes mellitus.

Limitations of Use: The proportions of rapid-acting and intermediate-acting insulins in Humalog Mix75/25 and Humalog Mix50/50, and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 are fixed and do not allow for basal versus prandial dose adjustments.

Important Safety Information for Humalog Brand of Insulins and Lilly’s Non-Branded Insulin Lispro Products

Contraindications

Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50 are contraindicated during episodes of hypoglycemia and in patients who are hypersensitive to these insulins or any of their excipients.

Warnings and Precautions

Never share a Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, or Humalog Mix50/50 prefilled pen, cartridge, reusable pen compatible with Lilly 3 mL cartridges, or syringe between patients, even if the needle is changed. Patients using vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.

Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in insulin strength, manufacturer, type, injection site, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Any changes in insulin regimen should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. Due to reports of hyperglycemia and hypoglycemia, advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor blood glucose. For patients with type 2 diabetes, dosage adjustments of concomitant antidiabetic products may be needed.

Hypoglycemia: Severe hypoglycemia may be life threatening and can cause seizures or death. Hypoglycemia is the most common adverse reaction of Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50. Monitor blood glucose and increase monitoring frequency with changes to insulin dosage, use with glucose-lowering medications, meal pattern, physical activity; in patients with renal or hepatic impairment; and in patients with hypoglycemia unawareness.

Hypoglycemia Due to Medication Errors: Instruct patients to always check the insulin label before each injection to avoid medication errors. Humalog U-200 should not be transferred from the Humalog KwikPen to a syringe as overdose and severe hypoglycemia can occur.

Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50. If hypersensitivity reactions occur, discontinue the use of insulin and treat per standard of care until signs and symptoms resolve.

Hypokalemia: Hypokalemia may be life threatening. Insulins, including Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50, cause a shift in potassium from the extracellular to intracellular space possibly leading to hypokalemia, which, if untreated, may result in respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia (e.g., patients using potassium-lowering medications or medications sensitive to serum potassium concentrations).

Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists: Thiazolidinediones (TZDs), which are PPAR-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin, including Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50. This may lead to or exacerbate heart failure. Observe patients for signs and symptoms of heart failure and consider discontinuation or dose reduction of the PPAR-gamma agonist.

Hyperglycemia and Ketoacidosis Due to Insulin Pump Device Malfunction: Malfunction of the insulin pump device, infusion set, or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Patients using subcutaneous insulin infusion pumps must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure.

Adverse Reactions

Adverse reactions associated with Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50 include hypoglycemia, hypokalemia, allergic reactions, injection-site reactions, lipodystrophy, pruritus, rash, weight gain, and peripheral edema.

Drug Interactions

Some medications may alter glucose metabolism, insulin requirements, and the risk for hypoglycemia or hyperglycemia. Signs of hypoglycemia may be reduced or absent in patients taking anti-adrenergic drugs. Particularly close monitoring may be required.

Please see links to Full Prescribing Information, Patient Information and Instructions for Use at the bottom of the page for more information.

HI BOI SP U100 75/25 HCP ISI 10JAN2020

Indication for Lyumjev

Lyumjev is indicated to improve glycemic control in adults with diabetes mellitus.

Important Safety Information for Lyumjev

Contraindications

Lyumjev is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin lispro-aabc or one of the excipients in Lyumjev.

Warnings and Precautions

Never Share a Lyumjev Prefilled Pen, Cartridge, or Syringe Between Patients, even if the needle is changed. Patients using Lyumjev vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.

Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in insulin strength, manufacturer, type, injection site, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Any changes in insulin regimen should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. Due to reports of hyperglycemia and hypoglycemia, advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor blood glucose. For patients with type 2 diabetes, dosage adjustments of concomitant antidiabetic products may be needed.

Hypoglycemia: Severe hypoglycemia may be life threatening, may lead to unconsciousness, and can cause seizures or death. Hypoglycemia is the most common adverse reaction of Lyumjev. Monitor blood glucose and increase monitoring frequency with changes to insulin dosage, use with glucose-lowering medications, meal pattern, physical activity; in patients with renal or hepatic impairment; and in patients with hypoglycemia unawareness.

Hypoglycemia Due to Medication Errors: Instruct patients to always check the insulin label before each injection to avoid medication errors. Lyumjev U-200 should not be transferred from the Lyumjev KwikPen to a syringe as overdose and severe hypoglycemia can occur.

Hypokalemia: Hypokalemia may be life threatening. Insulins, including Lyumjev, cause a shift in potassium from the extracellular to intracellular space possibly leading to hypokalemia, which, if untreated, may result in respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia (e.g., patients using potassium-lowering medications or medications sensitive to serum potassium concentrations)

Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with Lyumjev. If hypersensitivity reactions occur, discontinue the use of insulin and treat per standard of care until signs and symptoms resolve.

Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists: Thiazolidinediones (TZDs), which are PPAR-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin, including Lyumjev. This may lead to or exacerbate heart failure. Observe patients for signs and symptoms of heart failure and consider discontinuation or dose reduction of the PPAR-gamma agonist.

Adverse Reactions

Adverse reactions associated with Lyumjev include hypoglycemia, hypokalemia, allergic reactions, injection-site reactions, lipodystrophy, localized cutaneous amyloidosis, pruritus, rash, weight gain, and peripheral edema.

Drug Interactions

Some medications may alter glucose metabolism, insulin requirements, and the risk for hypoglycemia or hyperglycemia. Signs of hypoglycemia may be reduced or absent in patients taking anti-adrenergic drugs. Particularly close monitoring may be required.

Please click to access Lyumjev Full Prescribing Information including Patient Prescribing Information and Instructions for Use for the Lyumjev U-100 KwikPen and vial. Please click to access Instructions for Use for the Lyumjev U-200 KwikPen.

UR HCP ISI 15JUN2020

    • Humalog Full Prescribing Information
    • Humalog U-100 Patient Prescribing Information
    • Humalog U-200 Patient Prescribing Information
    • Humalog Mix75/25 Full Prescribing Information
    • Humalog Mix75/25 Patient Prescribing Information
    • Humalog Mix50/50 Full Prescribing Information
    • Humalog Mix50/50 Patient Prescribing Information
    • Insulin Lispro Injection Full Prescribing Information
    • Insulin Lispro Injection Patient Prescribing Information
    • Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 Prescribing Information
    • Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 Patient Prescribing Information
    • Lyumjev Full Prescribing Information
    • Lyumjev Patient Prescribing Information
    • Visit LillyMedical.com
    • Humalog U-100 KwikPen Instructions for Use
    • Humalog Junior KwikPen Instructions for Use
    • Humalog U-100 Vial Instructions for Use
    • Humalog U-200 KwikPen Instructions for Use
    • Humalog Mix75/25 KwikPen Instructions for Use
    • Humalog Mix75/25 Vial Instructions for Use
    • Humalog Mix50/50 KwikPen Instructions for Use
    • Humalog Mix50/50 Vial Instructions for Use
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

To speak to customer support:
Call (800) 545-5979

This site is intended for US healthcare professionals only.

Models used for illustrative purposes only. Not actual patients or healthcare providers.

PP-DB-US-0733 10/22 ©Lilly USA, LLC 2022. All rights reserved.

Humalog®, Humalog® KwikPen®, and Humalog® Junior KwikPen® are registered trademarks of Eli Lilly and Company, its subsidiaries, or affiliates. Humalog® Mix75/25™, Humalog® Mix50/50™, Humalog® Mix75/25™ KwikPen®, and Humalog® Mix50/50™ KwikPen® are trademarks of Eli Lilly and Company.

Lyumjev® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

Terms of Use Privacy Statement Accessibility Statement Sitemap
Lilly.com